CEO confidence down
February 19, 2016
KINETICOS, in partnership
with Ipsos Healthcare and Demy-
Colton Life Science Advisors, have
announced the Q4 2015 results of
the Biopharma CEO Confidence
Index, revealing a downward trend.
The measure is a forward-looking
indicator designed to measure
ceo confidence in the biopharma
industry’s economy.
Those ceos with high confidence
levels of being able to raise capital
in the next 18 months declined
from 53% in Q3 to 39% in Q4, while
those who viewed the current deal
landscape as good, declined from
82% to 61% in the same period.
CEOs very confident in their
ability to deliver therapies in three
to five years remained stable in
Q4 at 91% compared to 86% in
Q3 but only 33% of ceos believed
transaction values were increasing
in Q4, compared to 59% in Q3, the
report said.
The data also showed that
oncology (37%) and neurology
(33%) remain the focus of licensing
transactions.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Feb 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Feb 16
